A large number of studies have been published addressing this question, with only a very limited number of biomarkers making it into clinical routine, such as immunohistochemical PD-L1 scoring and the tumor mutational burden (TMB), with its inherent limitations e.g. the need for tissue biopsy [6–8]. This evidence concerns the gene CD274 and neoplasm.